CLAS Stock Overview
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Claritas Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.025 |
| 52 Week High | CA$0.27 |
| 52 Week Low | CA$0.025 |
| Beta | 2.6 |
| 1 Month Change | 0% |
| 3 Month Change | -16.67% |
| 1 Year Change | -90.39% |
| 3 Year Change | -95.83% |
| 5 Year Change | -98.68% |
| Change since IPO | -99.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLAS | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | 5.0% | 0.9% |
| 1Y | -90.4% | 91.8% | 7.4% |
Rentabilidad frente al sector: CLAS obtuvo unos resultados inferiores a los del sector Canadian Pharmaceuticals , que el año pasado arrojó un rendimiento del -32.9%.
Rentabilidad vs. Mercado: CLAS obtuvo unos resultados inferiores a los del mercado Canadian, que fue del -0.8% el año pasado.
Price Volatility
| CLAS volatility | |
|---|---|
| CLAS Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 14.1% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CA Market | 18.2% |
| 10% least volatile stocks in CA Market | 3.1% |
Precio estable de las acciones: CLASha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de CLAS en el último año.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Bob Farrell | https://claritaspharma.com |
Claritas Pharmaceuticals, Inc. Fundamentals Summary
| CLAS fundamental statistics | |
|---|---|
| Market cap | CA$944.66k |
| Earnings (TTM) | CA$2.50m |
| Revenue (TTM) | n/a |
0.4x
P/E Ratio0.0x
P/S RatioIs CLAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLAS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$1.80m |
| Earnings | US$1.81m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.048 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 16.4% |
How did CLAS perform over the long term?
See historical performance and comparison